Literature DB >> 32840587

Therapies Offered at Residential Addiction Treatment Programs in the United States.

Tamara Beetham1, Brendan Saloner2, Marema Gaye3, Sarah E Wakeman4, Richard G Frank5, Michael L Barnett3.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32840587      PMCID： PMC7448823          DOI： 10.1001/jama.2020.8969

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  2 in total

1.  Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Authors:  Sarah E Wakeman; Marc R Larochelle; Omid Ameli; Christine E Chaisson; Jeffrey Thomas McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi
Journal:  JAMA Netw Open       Date:  2020-02-05

2.  Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.

Authors:  David A Fiellin; Richard S Schottenfeld; Christopher J Cutter; Brent A Moore; Declan T Barry; Patrick G O'Connor
Journal:  JAMA Intern Med       Date:  2014-12       Impact factor: 21.873
  2 in total
  8 in total

1.  Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020.

Authors:  Jonathan Cantor; David Powell; Aaron Kofner; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2021-09-27       Impact factor: 4.492

Review 2.  Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission.

Authors:  Keith Humphreys; Chelsea L Shover; Christina M Andrews; Amy S B Bohnert; Margaret L Brandeau; Jonathan P Caulkins; Jonathan H Chen; Mariano-Florentino Cuéllar; Yasmin L Hurd; David N Juurlink; Howard K Koh; Erin E Krebs; Anna Lembke; Sean C Mackey; Lisa Larrimore Ouellette; Brian Suffoletto; Christine Timko
Journal:  Lancet       Date:  2022-02-02       Impact factor: 202.731

3.  The role of stigma in U.S. primary care physicians' treatment of opioid use disorder.

Authors:  Elizabeth M Stone; Alene Kennedy-Hendricks; Colleen L Barry; Marcus A Bachhuber; Emma E McGinty
Journal:  Drug Alcohol Depend       Date:  2021-02-16       Impact factor: 4.492

4.  Robustness of estimated access to opioid use disorder treatment providers in rural vs. urban areas of the United States.

Authors:  Mathew V Kiang; Michael L Barnett; Sarah E Wakeman; Keith Humphreys; Alexander C Tsai
Journal:  Drug Alcohol Depend       Date:  2021-09-24       Impact factor: 4.492

5.  Multicenter Observational/Exploratory Study Addressed to the Evaluation of the Effectiveness and Safety of Pharmacological Therapy in Opioid-Dependent Patients in Maintenance Therapy in Southern Italy.

Authors:  Fatima Maqoud; Giada Fabio; Nunzio Ciliero; Marina Antonacci; Francesca Mastrangelo; Giorgio Sammarruco; Roberto Cataldini; Gabriella Schirosi; Salvatore De Fazio; Domenico Tricarico
Journal:  Pharmaceutics       Date:  2022-02-21       Impact factor: 6.321

6.  Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.

Authors:  Daniel M Hartung; Sheila Markwardt; Kirbee Johnston; Jonah Geddes; Robin Baker; Gillian Leichtling; Christi Hildebran; Brian Chan; Ryan R Cook; Dennis McCarty; Udi Ghitza; P Todd Korthuis
Journal:  Addict Sci Clin Pract       Date:  2022-08-19

7.  Gender disparities in opioid treatment progress in methadone versus counseling.

Authors:  Erick Guerrero; Hortensia Amaro; Yinfei Kong; Tenie Khachikian; Jeanne C Marsh
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-06-23

8.  Development of an unannounced standardized patient protocol to evaluate opioid use disorder treatment in pregnancy for American Indian and rural communities.

Authors:  A Taylor Kelley; Marcela C Smid; Jacob D Baylis; Elizabeth Charron; Amy E Binns-Calvey; Shayla Archer; Saul J Weiner; Lori Jo Begaye; Gerald Cochran
Journal:  Addict Sci Clin Pract       Date:  2021-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.